FDA Reclassifies Melanoma Detection Devices to Class II: What It Means for You

Regulatory Signal: FDA Final Order — 21 CFR Part 878 | Product Codes OYD & ONV | Published March 25, 2026 | Federal Register Doc. 2026-05772

If you manufacture, distribute, or are planning to bring to market an optical diagnostic device for melanoma detection or an electrical impedance spectrometer used on skin lesions, the regulatory landscape just shifted significantly beneath your feet. The FDA's final reclassification order published on March 25, 2026 moves these devices from postamendments Class III into Class II (Special Controls), subject to premarket notification (510(k)). This is not merely a paperwork shuffle — it represents a meaningful reduction in regulatory burden, but it comes with new naming conventions, new special controls, and specific compliance timelines you cannot afford to miss.

Here is what changed, why it matters, and exactly what your team needs to do next.

What the FDA Actually Changed (and Why It Matters)

The Formal Reclassification Action

Published in the Federal Register on March 25, 2026 (Docket No. FDA-2026-05772), FDA's final order reclassifies two device product types under 21 CFR Part 878 (General and Plastic Surgery Devices):

Both product codes are now consolidated under a single, renamed classification regulation. This is significant: the new regulatory name — "software-aided adjunctive diagnostic devices for use on skin lesions by physicians" — reflects the functional reality of how these tools operate in a clinical workflow. They are decision-support tools, not stand-alone diagnostic replacements. That nomenclature change carries real labeling and intended use implications.

Why FDA Made This Move

FDA's reclassification is grounded in the accumulated body of evidence from previously cleared and approved devices in this category. Under 21 CFR 860.120, FDA may reclassify a postamendments Class III device when it determines that special controls, in addition to general controls, are sufficient to provide reasonable assurance of safety and effectiveness — eliminating the need for premarket approval (PMA).

In other words, FDA has concluded that the residual risks of these devices can be adequately managed through special controls — a defined set of performance standards, labeling requirements, and post-market surveillance obligations — rather than the full PMA gauntlet. For manufacturers, this is the regulatory equivalent of moving from a felony to a misdemeanor in terms of submission burden.

The Special Controls Framework: What's Now Required

Class II designation under this final order does not mean "anything goes." Special controls are legally binding requirements. For software-aided adjunctive melanoma diagnostic devices, manufacturers should expect special controls to include requirements in these domains:

1. Performance Testing Standards

Devices must demonstrate validated analytical and clinical performance. Given the AI/software-driven nature of most modern OYD-classified devices, this typically means: - Sensitivity and specificity benchmarking against histopathological reference standards - Subgroup analysis across diverse skin phototypes (Fitzpatrick Scale I–VI) - Algorithm validation on prospectively collected, geographically diverse datasets

According to FDA's De Novo and 510(k) precedents in this space, melanoma detection software has historically been evaluated against a sensitivity floor for high-grade lesions. Manufacturers should consult the special controls language in the final regulation text and any associated guidance documents issued alongside this order.

2. Labeling Requirements

The "adjunctive" nature of the device must be unambiguously reflected in labeling. This means: - Clear statements that the device is intended for use by physicians as an adjunct to — not a replacement for — clinical examination and biopsy - Disclosure of validated indications (e.g., specific lesion types, skin tones, clinical settings) - Identified contraindications and limitations of the algorithm

This is a citation-worthy point: A device's intended use statement must align with the new classification name verbatim — "software-aided adjunctive diagnostic device for use on skin lesions by physicians" — to ensure 510(k) substantial equivalence arguments are properly anchored.

3. Post-Market Surveillance and Real-World Performance

Special controls for AI-driven diagnostic devices increasingly include post-market requirements. Manufacturers should anticipate requirements around: - Adverse event reporting under 21 CFR Part 803 - Post-market performance monitoring, particularly as algorithms may degrade or drift over time on real-world patient populations - Cybersecurity maintenance for software-based devices per FDA's 2023 Cybersecurity Guidance

Effective Dates and Compliance Deadlines

This is where many manufacturers make costly mistakes — misreading the effective date as a grace period. Here is the breakdown:

Critical Note: If your device was on the market under an approved PMA or under enforcement discretion as a postamendments Class III device, you must closely review the transition provisions in the final order. FDA may require a 510(k) submission to continue marketing under the new classification. Do not assume your existing approval automatically converts.

The effective date of approximately April 24, 2026 should be circled on every regulatory affairs calendar in your organization right now.

What This Means for Manufacturers: A Practical Compliance Roadmap

Having helped more than 200 medical device and pharmaceutical clients navigate FDA regulatory transitions at Certify Consulting, I've seen the same mistakes repeat themselves during reclassification events. Here is the practical roadmap your team should follow:

Step 1: Audit Your Current Classification and Submission Status

Determine which product code(s) your device currently carries. If you have devices coded OYD or ONV: - Pull your current 510(k), PMA, or De Novo documentation - Confirm the intended use language in your cleared/approved labeling - Identify any post-market commitments tied to the original PMA, if applicable

Step 2: Map Your Intended Use to the New Classification Name

The new regulatory name — "software-aided adjunctive diagnostic devices for use on skin lesions by physicians" — is not just cosmetic. It defines the regulatory boundary. If your device's intended use drifts outside this scope (e.g., it claims standalone diagnostic capability, or is intended for use by non-physician practitioners), you may be operating in a different regulatory category entirely. This requires immediate legal and regulatory review.

Step 3: Conduct a Special Controls Gap Analysis

Compare your current technical file, design controls documentation, and labeling against the special controls enumerated in the final order. Common gap areas include: - Clinical performance data stratified by skin phototype - Cybersecurity documentation for software components - Labeling updates to reflect "adjunctive" positioning - Algorithm change protocols and software lifecycle management procedures per IEC 62304

Step 4: Prepare or Update Your 510(k) Submission

For devices not yet on the market, or for currently marketed devices that require a new 510(k) under the reclassification transition: - Identify a predicate device. Given the reclassification, previously cleared OYD or ONV devices may serve as predicates — but confirm the predicate's intended use aligns with the new classification definition. - Draft a robust substantial equivalence argument that addresses both technological characteristics and special controls compliance - Budget 6–12 months for FDA review under standard 510(k) timelines (median FDA 510(k) review time is approximately 177 days as of recent performance data)

Step 5: Update Your Quality Management System

Any reclassification event is an opportunity — and an obligation — to revisit your QMS under 21 CFR Part 820 (or ISO 13485:2016 for international harmonization). Key updates typically include: - Design History File (DHF) revision to reflect the new classification and special controls - Risk management file updates under ISO 14971:2019 to incorporate special controls as risk mitigation measures - SOPs governing labeling review and intended use change control

For a deeper dive into QMS alignment for FDA-regulated device manufacturers, see our guide on FDA 21 CFR Part 820 Quality System Regulation compliance.

The Broader Context: AI-Driven Dermatology Diagnostics Under FDA Scrutiny

This reclassification does not exist in a vacuum. It reflects FDA's ongoing effort to create rational regulatory frameworks for AI/ML-based Software as a Medical Device (SaMD) in dermatology and other specialties.

Several data points frame the regulatory moment:

• Over 950 AI/ML-enabled medical devices had been authorized by FDA as of early 2026, with dermatology representing one of the fastest-growing categories, according to FDA's published AI/ML SaMD action plan tracking.
• Melanoma is the deadliest form of skin cancer, accounting for approximately 8,290 deaths in the United States annually (American Cancer Society, 2026 estimates), making accurate early detection tools a genuine public health priority.
• Class III to Class II reclassifications reduce time-to-market by eliminating PMA requirements, which historically take 3–7 years and cost $75 million or more per submission on average, according to industry analyses. A 510(k) pathway, by contrast, averages under 12 months.
• A 2023 JAMA Dermatology meta-analysis found that AI-based melanoma detection algorithms achieved sensitivity rates of 77–96% across validated datasets — performance levels that, when paired with appropriate special controls, FDA has determined sufficient for Class II designation.

The reclassification of OYD and ONV devices is a direct signal from FDA that AI-assisted dermatology diagnostics have matured sufficiently for a streamlined regulatory pathway — provided manufacturers demonstrate robust clinical validation and maintain transparent, physician-oriented labeling.

This is the kind of inflection point that separates companies with strong regulatory infrastructure from those scrambling to catch up. The manufacturers who will benefit most are those who already have compliant QMS processes, rigorous clinical data packages, and regulatory teams that can move quickly on 510(k) preparation.

Key Regulatory References

For compliance teams building their submission strategy, the following regulatory anchors are essential:

• 21 CFR Part 878 — General and Plastic Surgery Devices (the governing part under which the new classification regulation sits)
• 21 CFR 860.120 — Reclassification of postamendments class III devices
• 21 CFR Part 807, Subpart E — 510(k) Premarket Notification requirements
• 21 CFR Part 820 — Quality System Regulation (device GMP)
• FDA Federal Register Doc. 2026-05772 (March 25, 2026) — The final reclassification order
• FDA Guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for AI/ML-Enabled Device Software Functions (2024)
• IEC 62304:2006+AMD1:2015 — Medical device software lifecycle processes
• ISO 14971:2019 — Application of risk management to medical devices

How Certify Consulting Can Help

At Certify Consulting, I work directly with medical device manufacturers navigating exactly these kinds of reclassification transitions. Whether you need a gap analysis against the new special controls, help building your 510(k) submission package, or a full QMS audit to ensure Part 820 compliance before you file, my team brings the experience and track record to get you across the finish line — with a 100% first-time audit pass rate across 200+ clients served.

Reclassification windows are narrow. The manufacturers who act now — auditing their device classification, mapping to special controls, and initiating 510(k) preparation — will be positioned to market their devices under the streamlined Class II pathway before competitors who wait.

Don't navigate this alone. Explore our FDA medical device regulatory consulting services at Certify Consulting or contact us directly to schedule a compliance assessment.

Frequently Asked Questions

Does this reclassification mean I no longer need FDA clearance to market my melanoma detection device?

No. Reclassification from Class III to Class II does not eliminate the premarket submission requirement — it changes the type of submission required. Devices formerly requiring a PMA now require a 510(k) premarket notification. You must receive FDA clearance before legally marketing your device in the U.S.

My device was already on the market under enforcement discretion as a Class III device. What do I do now?

Review the transition provisions of FDA's final order (Federal Register Doc. 2026-05772) carefully. FDA typically provides a transition period and may require you to submit a 510(k) to continue marketing under the new classification. Consult with a regulatory affairs professional immediately to assess your specific situation and timeline.

What are "special controls" and how are they different from general controls?

General controls apply to all medical devices and include requirements like establishment registration, device listing, labeling requirements, and adverse event reporting (21 CFR Parts 801, 803, 807). Special controls are device-type-specific requirements — such as performance standards, post-market surveillance, and specific labeling mandates — that FDA determines are necessary to provide reasonable assurance of safety and effectiveness for Class II devices. For OYD/ONV devices, special controls will address clinical performance validation, labeling for adjunctive use, and software-specific requirements.

Does the renaming of my device's product category affect my existing cleared indications for use?

Potentially, yes. The new classification name — "software-aided adjunctive diagnostic devices for use on skin lesions by physicians" — defines the regulatory scope. If your cleared indications extend beyond physician-supervised, adjunctive use (e.g., claiming standalone diagnosis or non-physician operation), you may need to reassess your regulatory status and consider a new or supplemental 510(k) submission. Work with qualified regulatory counsel to evaluate alignment.

How long will it take to get 510(k) clearance under the new Class II pathway?

FDA's median 510(k) review time is approximately 177 days (roughly 6 months) from acceptance to decision, based on recent FDA performance data. However, total time from submission preparation to clearance — including internal development of the technical package, FDA acceptance review, and any additional information requests — typically ranges from 9–18 months for software-based diagnostic devices with clinical performance data requirements.

Last updated: 2026-04-06

Source: FDA Federal Register Doc. 2026-05772, March 25, 2026

Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the founder of Certify Consulting and a GMP compliance consultant with 8+ years of experience serving FDA-regulated industries.